JP5988961B2 - 心筋細胞を発生させるための方法 - Google Patents

心筋細胞を発生させるための方法 Download PDF

Info

Publication number
JP5988961B2
JP5988961B2 JP2013508153A JP2013508153A JP5988961B2 JP 5988961 B2 JP5988961 B2 JP 5988961B2 JP 2013508153 A JP2013508153 A JP 2013508153A JP 2013508153 A JP2013508153 A JP 2013508153A JP 5988961 B2 JP5988961 B2 JP 5988961B2
Authority
JP
Japan
Prior art keywords
fibroblasts
polypeptide
gata4
tbx5
mef2c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013508153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013524837A (ja
JP2013524837A5 (enExample
Inventor
スリバスタバ，ディーパック
真樹 家田
真樹 家田
Original Assignee
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェイ． デヴィッド グラッドストーン インスティテューツ, ザ ジェイ． デヴィッド グラッドストーン インスティテューツ filed Critical ザ ジェイ． デヴィッド グラッドストーン インスティテューツ
Publication of JP2013524837A publication Critical patent/JP2013524837A/ja
Publication of JP2013524837A5 publication Critical patent/JP2013524837A5/ja
Application granted granted Critical
Publication of JP5988961B2 publication Critical patent/JP5988961B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
JP2013508153A 2010-04-28 2011-04-26 心筋細胞を発生させるための方法 Expired - Fee Related JP5988961B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32898810P 2010-04-28 2010-04-28
US61/328,988 2010-04-28
US36429510P 2010-07-14 2010-07-14
US61/364,295 2010-07-14
PCT/US2011/033938 WO2011139688A2 (en) 2010-04-28 2011-04-26 Methods for generating cardiomyocytes

Publications (3)

Publication Number Publication Date
JP2013524837A JP2013524837A (ja) 2013-06-20
JP2013524837A5 JP2013524837A5 (enExample) 2015-05-28
JP5988961B2 true JP5988961B2 (ja) 2016-09-07

Family

ID=44904333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508153A Expired - Fee Related JP5988961B2 (ja) 2010-04-28 2011-04-26 心筋細胞を発生させるための方法

Country Status (4)

Country Link
US (2) US9517250B2 (enExample)
EP (1) EP2563907B1 (enExample)
JP (1) JP5988961B2 (enExample)
WO (1) WO2011139688A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US7907222B2 (en) 2005-09-08 2011-03-15 Universal Electronics Inc. System and method for simplified setup of a universal remote control
US11769398B2 (en) 2005-09-08 2023-09-26 Universal Electronics Inc. System and method for widget-assisted setup of a universal remote control
US9852615B2 (en) 2011-03-25 2017-12-26 Universal Electronics Inc. System and method for facilitating appliance control via a smart device
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
US9017661B2 (en) 2011-02-22 2015-04-28 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
US20140289882A1 (en) * 2011-07-19 2014-09-25 Oregon Health And Science University Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
US9828585B2 (en) 2011-08-30 2017-11-28 The J. David Gladstone Instututes Methods for generating cardiomyocytes
US9019435B2 (en) 2011-09-22 2015-04-28 Universal Electronics Inc. System and method for configuring controlling device functionality
US10593195B2 (en) 2011-10-28 2020-03-17 Universal Electronics Inc. System and method for optimized appliance control
US10937308B2 (en) 2011-10-28 2021-03-02 Universal Electronics Inc. System and method for optimized appliance control
US11756412B2 (en) 2011-10-28 2023-09-12 Universal Electronics Inc. Systems and methods for associating services and/or devices with a voice assistant
US9449500B2 (en) 2012-08-08 2016-09-20 Universal Electronics Inc. System and method for optimized appliance control
US11295603B2 (en) 2011-10-28 2022-04-05 Universal Electronics Inc. System and method for optimized appliance control
ES2685319T3 (es) 2011-11-09 2018-10-08 Cedars-Sinai Medical Center Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas
JP2013240308A (ja) * 2012-05-23 2013-12-05 Kagoshima Univ ヒトＥＳ／ｉＰＳ細胞における遺伝子発現方法
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
WO2014071323A2 (en) 2012-11-02 2014-05-08 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
ES2651716T3 (es) * 2012-11-02 2018-01-29 Cornell University Acondicionamiento angiogénico para potenciar la reprogramación celular cardiaca de fibroblastos del miocardio infartado
EP3060649A4 (en) 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
US11377639B2 (en) * 2013-11-15 2022-07-05 Wisconsin Alumni Research Foundation Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
DE102013114671B4 (de) 2013-12-20 2015-10-29 Universität Rostock Verfahren zur Erzeugung von Sinusknotenzellen ("Herz-Schrittmacherzellen") aus Stammzellen
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
US10760040B1 (en) 2014-07-03 2020-09-01 NanoCav, LLC Mechanical transfection devices and methods
US10081816B1 (en) 2014-07-03 2018-09-25 Nant Holdings Ip, Llc Mechanical transfection devices and methods
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
JPWO2016056438A1 (ja) * 2014-10-06 2017-10-05 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる心筋様細胞の作製用組成物
WO2016134293A1 (en) 2015-02-20 2016-08-25 Baylor College Of Medicine p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
CN118340951A (zh) * 2015-03-12 2024-07-16 株式会社艾迪科 使用脱细胞化组织的抗粘连材料和代用生物膜
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US10729789B2 (en) * 2016-03-01 2020-08-04 University Of Virginia Patent Foundation Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
EP3431593A4 (en) * 2016-03-15 2019-11-13 Keio University METHOD FOR THE DIRECT PREPARATION OF A CARDIGENT CELL OR MYOCARDIAL CELL FROM FIBROBLAST
BR112018070255A2 (pt) * 2016-03-30 2019-01-29 The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone reprogramação cardíaca direta melhorada.
US11433116B2 (en) 2016-04-14 2022-09-06 Cedars-Sinai Medical Center GJA1 isoforms protect against metabolic stress
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3474868A4 (en) * 2016-06-27 2020-07-29 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone MODIFIED GLYCOPROTEINS.
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018055235A1 (en) 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CA3067863A1 (en) * 2017-06-21 2018-12-27 Mogrify Limited Cell reprogramming to cardiomyocytes
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN111684059A (zh) * 2018-01-30 2020-09-18 株式会社片冈制作所 心肌细胞的制备方法
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
AU2020267561A1 (en) * 2019-05-08 2021-12-23 Capricor, Inc. Therapeutically active cells and exosomes
JP7592251B2 (ja) * 2019-06-06 2024-12-02 プレジデント アンド フェローズ オブ ハーバード カレッジ 心筋細胞及び組成物ならびにそれらを生成する方法
WO2021050877A1 (en) * 2019-09-11 2021-03-18 Icahn School Of Medicine At Mount Sinai Compositions including molecules of modified mrna and methods of using the same
JP7514546B2 (ja) * 2019-12-03 2024-07-11 学校法人自治医科大学 心筋細胞の成熟方法、心筋細胞の成熟度評価方法、成熟心筋細胞の純化方法、心筋細胞成熟度評価装置、心筋細胞成熟度評価プログラム、及び心筋細胞成熟キット
AU2021259422A1 (en) 2020-04-20 2022-12-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド プラコフィリン２遺伝子治療の方法および組成物
CN113046308A (zh) * 2021-03-05 2021-06-29 苏州大学附属第二医院 促进心脏损伤后修复的一类新型成纤维细胞及其标识方法
WO2023201207A1 (en) 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
US20260224660A1 (en) 2023-01-10 2026-08-06 Keio University Cardiac dilatation function improving agent, and method for screening for cardiac dilatation function improving agent
WO2025129079A1 (en) * 2023-12-13 2025-06-19 Tenaya Therapeutics, Inc. Cardiac-specific promoters for gene therapy
WO2026009883A1 (ja) * 2024-07-03 2026-01-08 慶應義塾 心筋ダイレクトリプログラミングのための組換えアデノ随伴ウイルスベクター

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
EP0855024A4 (en) 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
FR2751345B1 (fr) 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
WO2000073423A1 (en) 1999-06-01 2000-12-07 Chugai Seiyaku Kabushiki Kaisha Packaging cell
ATE324321T1 (de) 2000-08-31 2006-05-15 Edwin Lundgren Steuervorrichtung für einen lenkdrachen an einem boot
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
EP1412479A4 (en) 2001-07-12 2004-07-28 Geron Corp CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS
US20050043260A1 (en) * 2003-04-21 2005-02-24 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US20090275032A1 (en) 2005-08-01 2009-11-05 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator
US7620013B2 (en) * 2005-12-21 2009-11-17 Broadcom Corporation Method and system for decoding control channels using repetition redundancy
US20100135970A1 (en) 2006-10-27 2010-06-03 Caritas St. Elizabeth Medical Center Of Boston, In Methods for Reprogramming Adult Somatic Cells and Uses Thereof
WO2008088882A2 (en) * 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
WO2008151387A1 (en) 2007-06-14 2008-12-18 Cytomatrix Pty Ltd Method of initiating cardiomyocyte differentiation
US20090081170A1 (en) * 2007-09-13 2009-03-26 Paul Riley Cardiac progenitor cells
KR101532442B1 (ko) 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
WO2009086015A2 (en) 2007-12-21 2009-07-09 Boston Scientific Scimed, Inc. Flexible stent-graft device having patterned polymeric coverings
US20090208465A1 (en) 2008-02-15 2009-08-20 Keio University Method of treating neural defects
CN102083982A (zh) 2008-04-07 2011-06-01 纽珀滕索有限公司 通过rna干扰引入复能基因而重编程细胞
US9102920B2 (en) 2008-05-06 2015-08-11 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
EP2297332A4 (en) 2008-06-13 2012-03-21 Univ Kyoto METHOD AND PLATFORMS FOR THE DRUG DISCOVERY
US20100150879A1 (en) * 2008-10-16 2010-06-17 Wary Kishore K Methods for the detection, isolation, and use of lipid phosphate phosphatase-3-positive stem cells
US20120115225A1 (en) 2009-04-23 2012-05-10 Xu C W Reprogramming of somatic cells with purified proteins
US20100330044A1 (en) 2009-06-30 2010-12-30 Universite Libre De Bruxelles Mesp1 as a master regulator of multipotent cardiovascular progenitor specification and uses thereof
EP2542669B1 (en) 2010-03-05 2015-01-21 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
WO2011163531A2 (en) * 2010-06-23 2011-12-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
US9828585B2 (en) 2011-08-30 2017-11-28 The J. David Gladstone Instututes Methods for generating cardiomyocytes

Also Published As

Publication number Publication date
EP2563907A4 (en) 2014-03-05
US9517251B2 (en) 2016-12-13
JP2013524837A (ja) 2013-06-20
US9517250B2 (en) 2016-12-13
EP2563907B1 (en) 2019-06-19
WO2011139688A2 (en) 2011-11-10
US20130216503A1 (en) 2013-08-22
EP2563907A2 (en) 2013-03-06
WO2011139688A3 (en) 2012-03-01
US20140235526A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
EP2563907B1 (en) Methods for generating cardiomyocytes
JP6298405B2 (ja) 心筋細胞を生成するための方法
US20230310546A1 (en) Methods for inducing cell division of postmitotic cells
US20210180013A1 (en) Improved methods for inducing tissue regeneration and senolysis in mammalian cells
US20120009158A1 (en) VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF
JP2004511209A (ja) 細胞の脱分化及び組織の再生のための組成物及び方法
US20240226178A1 (en) Electrophysiological modification to suppress arrhythmias
EP3431593A1 (en) Method for directly producing cardiac precursor cell or myocardial cell from fibroblast
US20130011373A1 (en) Side population cells in cardiac repair
WO2014141392A1 (ja) 平行線維性結合組織の製造方法
US12173322B2 (en) Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof
WO2023004345A1 (en) Compositions and methods for enhancing cardiomyocyte transplant engraftment
Kalargyrou Determining the molecular mechanisms mediating cytoplasmic material transfer between photoreceptors in the transplantation paradigm
WO2006021459A1 (en) Compositions and methods for modulating cell differentiation
Barrett et al. RESEARCH ARTICLE Evaluation of human dermal fibroblasts directly reprogrammed to adipocyte-like cells as a metabolic disease model Jian-Hua Chen1, 2, Kim Jee Goh1, 2, Nuno Rocha1, 2, Matthijs P. Groeneveld1, 2, Marina Minic1, 2
Poudel Cell-based Gene Therapy for Mending Infarcted Hearts
HK1250931B (en) Methods for inducing cell division of postmitotic cells
WO2006021460A1 (en) Means and methods for generating cardiomyocytes and tissue and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160809

R150 Certificate of patent or registration of utility model

Ref document number: 5988961

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees